EU/3/13/1103

About

On 8 February 2013, orphan designation (EU/3/13/1103) was granted by the European Commission to SciPharm S.a.r.L, Luxembourg, for treprostinil sodium for the treatment of chronic thromboembolic pulmonary hypertension.

Key facts

Active substance
Treprostinil sodium
Disease / condition
Treatment of chronic thromboembolic pulmonary hypertension
Date of first decision
08/02/2013
Outcome
Positive
EU designation number
EU/3/13/1103

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

SciPharm S.a.r.L
7, Fausermillen, L-6689 Mertert
Luxembourg
Telephone: +352 621 787119
E-mail: office@scipharm.eu

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating